Arcturus Therapeutics Gets $3M From Cystic Fibrosis Foundation

socalTECH

San Diego-based Arcturus Therapeutics , a developer of mRNA-based treatments for disease, has signed a deal to receive up to $3M in funding from the Cystic Fibrosis Foundation Therapeutics, a nonprofit which supports drug discovery and development. The company said the $3M will go to advance LUNAR-CF, a novel messenger RNA (mRNA) therapeutic formulated with Arcturus' drug delivery technology.

Arcturus Therapeutics Gets $5M

socalTECH

San Diego-based Arcturus Therapeutics , a developer of RNAi technology, said it has raised $5M in a Series A funding round. According to Arcturus, the funding came from multiple private capital,, high net worth investors from Canada, Japan, and the United States. arcturus therapeutics venture capital rnai lifescience biotech biopharmaceuticals

Arcturus Therapeutics Gets $1.3M

socalTECH

San Diego-based Arcturus Therapeutics , which is developing RNAi therapeutics to treat disease, said this morning that it has raised $1.3M Arcturus Therapeutics is headed by Joseph E. arcturus therapeutics venture capital rnai lifescience biotech in a seed fudning round. The company said the round came from multiple, high net-worth private investors from the U.S. and Canada. Names of those investors were not announced. Payne. READ MORE>>.

Settlement Ends Fight at Arcturus Therapeutics; New Board Named

Xconomy

The San Diego RNA drug developer Arcturus Therapeutics (NASDAQ: ARCT ) named four new board members Tuesday, after the four directors who fired founding CEO Joseph Payne resigned as part of a settlement agreement that was approved Monday by an Israeli court.

Arcturus Get Exit At Pliant

socalTECH

Pasadena-based venture capital firm Arcturus Capital has scored an exit out of its portfolio this morning, as Milpitas, California-based Pliant Technology was acquired by SanDisk in a deal worth $327M. Arcturus first invested in Pliant in 2007. capital venture sandisk pliant acquisition merger exit arcturus

Litigation in Israel and U.S. Mires RNA Drug Developer Arcturus

Xconomy

In the five years since it was founded, San Diego-based Arcturus Therapeutics (NASDAQ: ARCT ) says it has built a versatile platform for developing a variety of RNA-based medicines.

Arcturus Reinstates Fired CEO After Regime Change in Boardroom

Xconomy

The San Diego RNA drug developer Arcturus Therapeutics (NASDAQ: ARCT ) on Thursday reinstated fired CEO Joseph Payne and named ResMed (NYSE: RMD ) founder Peter Farrell as chairman of the company’s new board of directors.

Arcturus Therapeutics In Deal With Johnson & Johnson Innovation

socalTECH

San Diego-based RNA therapeutics developer Arcturus Therapeutics announced this morning that it is in a strategic collaboration deal, with Johnson & Johnson Innovation. The company said it has entered into a worldwide license agreement with Janssen Pharmaceuticals to develop and commercialize RNA-based drug products for specified diseases, using Arcturus' platform and technology.

Arcturus Board Schedules New Proxy Showdown with Ousted CEO

Xconomy

After postponing a May 7 shareholder vote in a power struggle for control of San Diego’s Arcturus Therapeutics (NASDAQ: ARCT ), the company’s board of directors has set a new date for its showdown with ousted CEO Joseph Payne.

Arcturus Fails to Ratify Auditor in Latest Fallout After CEO Firing

Xconomy

The schism between Arcturus Therapeutics’ board and its former chief executive is now putting the company at risk of missing key financial reporting deadlines, and possibly even losing its stock listing. Arcturus (NASDAQ: ARCT ) blamed the failure on Joseph Payne, who was fired as CEO on Feb.

RNA Specialist Arcturus Therapeutics Gets $3M R&D Grant for CF Drug

Xconomy

San Diego-based Arcturus Therapeutics said today Cystic Fibrosis Foundation Therapeutics has agreed to provide $3 million to fund research and development of a new messenger RNA drug that could be broadly used to treat cystic fibrosis patients. Arcturus says its technology can be used to make.

Xconomy Q&A: An Update with Arcturus Therapeutics CEO Joseph Payne

Xconomy

Things have been moving quickly in recent weeks for the San Diego RNA drug developer Arcturus Therapeutics. After initiating a reverse merger last month, Arcturus signed a research collaboration and worldwide licensing agreement with Janssen Pharmaceuticals, part of the Johnson & Johnson (NYSE: JNJ ) family of companies. Arcturus’s drugs are based on RNA, a molecule that carries the genetic instructions that cells use to make proteins.

Arcturus Board Sues Ex-CEO, Alleges Deceit, in Prelude to Proxy Fight

Xconomy

The board that fired Arcturus Therapeutics co-founder and CEO Joseph E. The allegations include attempting to give Arcturus assets to a friend’s biotech company for free, and operating a side business on company time.

Arcturus Proxy Fight Heats Up; Ex-CEO Responds to Board’s Charges

Xconomy

As a showdown stockholders meeting draws near for San Diego’s Arcturus Therapeutics (NASDAQ: ARCT ), a proxy battle is boiling down to an argument over who represents the best interests of shareholders in the tiny RNA drug company. In an April 3 letter addressed to the company’s four board members, Arcturus co-founder and ex-CEO Joseph E.

Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More

Xconomy

For the next five days, the oncology community’s attention will focus on Chicago. The Windy City is the home for the American Society of Clinical Oncology’s annual meeting, and it kicks off today. Many ASCO attendees will zero in on potential cancer drug combinations. They’re seen as the key to expanding the reach of caner immunotherapy, which still works on just a small fraction of patients.

News 48

Bio Roundup: Lung Cancer Questions, Migraine Races, HIV Battle & More

Xconomy

The top biopharma story of the week involves the fast-moving field of lung cancer, which, as we’ve written previously, has several key trials reading out in 2018. A big domino fell this week: data from a two-drug immunotherapy combination developed by Bristol-Myers Squibb. But the results, touted as positive, left more questions than answers. First, Bristol changed the trial’s structure midstream.

Bio Roundup: Funding Frenzy, Opioid Summit, Celgene Woes & More

Xconomy

Biotech startups rolled in cash this week. By our count, investors put more than $800 million into life-sciences startups in four days. The money came from a wide range of backers, not just traditional biotech venture firms. It’s early yet in 2018, but the current count could put life-sciences companies on pace to bust past last year’s $17.6 billion, a figure compiled in the Venture Monitor Report. Elsewhere, the U.S.

Bio Roundup: Biotech IPOs, Migraine Progress, Takeda Woos Shire & More

Xconomy

If the recent IPO activity seems to be on overdrive, it’s not your imagination. The number of companies filing to go public in the U.S. in the first quarter was up 44 percent compared to the same period a year ago, according to data compiled by consulting and accounting firm EY. Life science companies accounted for nearly one third of the quarter’s IPOs.

Ondax Closes Round At $2.2M

socalTECH

The round was led by Prospector Equity Capital and Arcturus Capital, and also included the Pasadena Angels and Tech Coast Angels.

Prolacta Ties With Susan G. Komen for the Cure

socalTECH

Prolacta is venture funded by Alta Ventures, DFJ Frontier, Arcturus Capital, DFJ Mercury, Funk Ventures, Phillip Capital, Gideon Hixon Fund, and Draper Associates L.P.

TrueCar Prices IPO

socalTECH

TrueCar is venture backed by backed by USAA, Capricorn Investment Group, Upfront Ventures, Anthem Ventures, Vulcan Capital Growth Equity, Peppy Capital Partners, Arcturus Venture Capital, along with others. Santa Monica-based TrueCar has priced its IPO, saying last night that it will sell 7.8 million shares of its stock at $9 per share. The pricing was below the company''s earlier, estimated IPO range of $12.00 to $14.00 per share. The company raised around $71.1M in the IPO offering.

Sorrento Therapeutics Gets $2.3M

socalTECH

Dr. Schuh was previously CEO and Director of AviaraDx, and also served at Arcturus Bioscience and Sequenom. San Diego-based Sorrento Therapeutics , a new biotechnology startup, has raised $2.3M in an equity funding round, according to a regulatory filing by the firm yesterday. Source of the funding was not disclosed. The firm is headed by Antonius Schuh, who serves as founding chairman and CEO; the firm's CFO is Steve Zaniboni.

Ondax Names New CEO

socalTECH

ONDAX is backed by Arcturus Capital, Prospector Equity Capital, and others. Monrovia-based Ondax , a manufacturer of holographic filters and semiconductor lasers for the industrial, defense, scientific and medical markets, announced this week that it has named Randy Heyler as its President and CEO.

Prolacta Tops $1M In Philanthoropic Donations

socalTECH

Prolacta is venture backed by such companies as Health Evolution Partners, Alta Partners, DFJ Frontier, Arcturus Capital, DFJ Mercury, Funk Ventures, Phillip Capital, Gideon Hixon Fund, and Draper Associates.

Prolacta Links With National Milk Bank

socalTECH

Prolacta is venture backed by Alta Partners, Arcturus Capital, DFJ Frontier, DFJ Mercury Venture Partners, Draper Associates, Draper Richards, Funk Ventures, Gideon Hixon Fund, and Philip Capital.

Xifin Hires CFO, Marketing VP

socalTECH

Zaniboni was also CFO for Arcturus Bioscience and Sequenom, XIFIN noted, adding that Taylor worked at IBM as a strategy executive prior to Acclerys. San Diego-based XIFIN , a publisher of hosted revenue cycle management software for diagnostic laboratories, reported Tuesday that it has added two members to its executive staff. The company said it has hired Steve Zaniboni as chief financial officer and R. William Taylor as vice president of marketing.

Zag: "Strongest Sales So far This Year"

socalTECH

Zag has previously received venture capital from such firms as Anthem Ventures, GRP Partners, the Tech Coast Angels, Capricorn Management, Capital One, and Arcturus Capital.

Zag 130

Zag Powers AAA Service

socalTECH

Zag is venture backed by Anthem Venture Partners, USAA, GRP Partners, Arcturus Capital, Callaway Cars and the Skoll Fund.

Zag 130

Zag Raises Funding

socalTECH

Zag has previously received funding from Anthem Ventures, Arcturus Capital, Capital One, Capricorn Management, GRP Partners, and the Tech Coast Angels.

Zag 130

Zag Raises $32.4M

socalTECH

Zag is venture backed by Anthem Ventures, Arcturus Capital, Capital One, Capricorn Management, GRP Partners, and the Tech Coast Angels, along with USAA.

Zag 130

Prolacta Bioscience Renews With Breast Milk Group

socalTECH

Prolacta is venture backed by Alta Partners, DFJ Frontier, Arcturus Capital, DFJ Mercury, Funk Ventures, Phillip Capital, Gideon Hixon Fund, and Draper Associates L.P.

Zag Spins Out TrueCar

socalTECH

The firm said it has scored Series A funding from Zag, Anthem Venture Partners, Global Retail Partners, Capricorn, Capital One Auto Finance, ARcturus Capital, Scott Painter, and co-founder Tom Taira. Santa Monica-based Zag, the online car buying software firm headed by former CarsDirect CEO Scott Painter, has spun out a new company called TrueCar, the firm said late Wednesday.

Zag 122

TrueCar Launches New Pricing Tool

socalTECH

The firm is venture backed by Anthem Ventures, Arcturus Capital, Capital One, Capricorn Management, and GRP Partners. Santa Monica-based TrueCar.com , the online automotive pricing startup headed up by Scott Painter, said Thursday that it has launched a new tool to help new car buyers. TrueCar said that it has launched a Best Local Price tool, which will allow car shoppers to search for the best local deals on a vehicle.

TrueCar Officially Launches Car Pricing Site

socalTECH

TrueCar is venture backed by Zag, Anthem Venture Partners, Global Retail Partners, Capricorn, Capital One Auto Finance, and Arcturus Capital. Santa Monica-based TrueCar has officially launched its new car pricing site today, saying that it is now providing consumers with details on the prices paid for people on cars in their area.

Digital Performance Raises $3.2M, Hires CEO

socalTECH

The round was led by Rincon Venture Partners, and also included Arcturus Capital and Momentum Venture Management. Long Beach-based Digital Performance, which develops technology for online sales efforts in the after market automotive parts sector, is announcing Monday that it has raised $3.2M in a Series A funding round.